Table 1.

Patients/tumour characteristics and treatment summary

Characteristics
Total	28
Age (years)
Median	61
Range	49–80
Sex
Male	25 (89.3%)
Female	3 (10.7%)
Primary tumour site
Oropharynx (total)	17 (60.7%)
p16 positive	5
p16 negative	1
p16 unknown (e.g. insufficient specimens)	11
Larynx	7 (25.0%)
Nasopharynx	4 (14.3%)
T stage
1	2 (7.1%)
2	14 (50.0%)
3	8 (28.6%)
4	4 (14.3%)
N stage
0	6 (21.4%)
1	2 (7.1%)
2 (total)	18 (64.3%)
2 (NPC)	1 (3.6%)
2a (non-NPC)	0 (0%)
2b (non-NPC)	11 (39.3%)
2c (non-NPC)	6 (21.4%)
3	2 (7.1%)
Staging (overall)
II	5 (17.9%)
III	5 (17.9%)
IV	18 (64.3%)
Treatment
Radiotherapy only	4 (14.3%)
Chemoradiotherapy (weekly cisplatin)	19 (67.6%)
Radiotherapy + cetuximab	3 (10.7%)
Induction chemotherapy followed by chemoradiotherapy (weekly cisplatin)	1 (3.6%)
Primary surgery	1 (3.6%)

NPC, nasopharyngeal cancer.